Divi's Laboratories Limited (DIVISLAB.NS) Bundle
Dive into Divi's Laboratories' latest performance: consolidated total income jumped to ₹2,529 crore in Q1 FY2026 (up 15% YoY) and ₹2,715 crore in Q2 FY2026 (up 27% YoY, 13% QoQ), taking H1 FY2026 to ₹5,389 crore (up 16% YoY); profitability surged with PBT at ₹733 crore (Q1) and ₹912 crore (Q2), PAT at ₹545 crore (Q1) and ₹689 crore (Q2) and a standout Q3 FY2025 net profit of ₹589 crore (+64.5% YoY) with EPS at ₹22.20; the business mix shows 40% revenue from custom synthesis and 88% of sales from exports (58% Europe, 14% US), while balance sheet strength is clear with consolidated assets of ₹18,151 crore, cash of ₹4,205 crore, receivables ₹2,521 crore, inventories ₹3,087 crore, a rock‑bottom debt‑to‑equity of 0.01, ROE 14.6% and book value of ₹511 per share; valuation sits at ~P/E 48x with market cap ~₹99,800 crore, stock near ₹3,780 and mixed analyst calls (13 buy, 6 hold, 13 sell), even as pricing pressures, logistics/geopolitical risks and peptide qualification timelines pose headwinds and projects like Kakinada Unit‑III (partial commercial ops from Jan 1, 2025) and nutraceutical expansion point to growth catalysts-read on for the detailed breakdown.
Divi's Laboratories Limited (DIVISLAB.NS) - Revenue Analysis
Divi's Laboratories reported sustained top-line growth across Q1 and Q2 FY2026, driven by custom synthesis demand, strong export traction and expanding nutraceutical sales. The company's consolidated total income and revenue from operations show healthy year-over-year and sequential momentum.- Consolidated Total Income Q1 FY2026: ₹2,529 crores (up 15% YoY from ₹2,197 crores in Q1 FY2025).
- Revenue from operations Q2 FY2026: ₹2,715 crores (up 27% YoY and 13% QoQ).
- Consolidated total income H1 FY2026 (ended Sep 30, 2025): ₹5,389 crores (up 16% vs ₹4,640 crores in H1 FY2025).
| Period | Consolidated Total Income (₹ crores) | YoY Growth | QoQ Growth |
|---|---|---|---|
| Q1 FY2026 | 2,529 | 15% | - |
| Q2 FY2026 | 2,715 | 27% | 13% |
| H1 FY2026 (Apr-Sep 2025) | 5,389 | 16% | - |
- Custom synthesis: 40% of total revenue - long-term contracts for APIs and intermediates serving global innovators.
- Exports: 88% of sales, geographically diversified with 58% to Europe and 14% to the US.
- Nutraceutical division: growing share due to improved production efficiencies and new product introductions aligned with long-term strategy.
| Category | Share (%) | Notes |
|---|---|---|
| Custom synthesis | 40% | Long-term contract manufacturing of APIs & intermediates |
| Exports (total) | 88% | 58% Europe, 14% US, remainder other markets |
| Europe | 58% | Primary export destination |
| United States | 14% | Secondary export market with growth potential |
| Domestic & Nutraceuticals | 12% | Nutraceuticals increasing share via efficiencies and NPD |
Divi's Laboratories Limited (DIVISLAB.NS) - Profitability Metrics
Divi's Laboratories delivered robust profitability gains across recent quarters, driven by volume growth, product mix improvements and operational leverage.
- PBT for Q1 FY2026: ₹733 crores (vs ₹604 crores in Q1 FY2025) - +21% YoY.
- PBT for Q2 FY2026: ₹912 crores - +26% YoY and +24% QoQ (vs Q1 FY2026).
- PAT for Q1 FY2026: ₹545 crores (vs ₹430 crores in Q1 FY2025) - +27% YoY.
- PAT for Q2 FY2026: ₹689 crores - +35% YoY and +26% QoQ.
- Net Profit for Q3 FY2025: ₹589 crores (vs ₹358 crores in Q3 FY2024) - +64.5% YoY.
- EPS for Q3 FY2025: ₹22.20 (vs ₹13.50 in Q3 FY2024), reflecting improved per‑share profitability.
| Metric | Q3 FY2024 | Q3 FY2025 | Q1 FY2025 | Q1 FY2026 | Q2 FY2026 |
|---|---|---|---|---|---|
| Net Profit (₹ crores) | 358 | 589 | - | - | - |
| Profit Before Tax (PBT) (₹ crores) | - | - | 604 | 733 | 912 |
| Profit After Tax (PAT) (₹ crores) | - | - | 430 | 545 | 689 |
| Earnings Per Share (EPS) (₹) | 13.50 | 22.20 | - | - | - |
| YoY / QoQ growth highlights | - | Net Profit +64.5% YoY | - | PBT +21% YoY; PAT +27% YoY | PBT +26% YoY, +24% QoQ; PAT +35% YoY, +26% QoQ |
Key operational drivers and investor considerations:
- Consistent YoY expansion in PBT and PAT indicates leverage on fixed costs and favorable product mix.
- Strong QoQ growth into Q2 FY2026 signals momentum rather than single‑quarter seasonality.
- EPS uplift in Q3 FY2025 confirms earnings accretion on a per‑share basis, benefiting shareholders directly.
- Monitor margin sustainability, working capital trends and R&D/CapEx cadence to assess durability of these gains.
For context on corporate priorities that underpin financial outcomes, see: Mission Statement, Vision, & Core Values (2026) of Divi's Laboratories Limited.
Divi's Laboratories Limited (DIVISLAB.NS) - Debt vs. Equity Structure
- Debt-to-Equity Ratio: 0.01 - indicates negligible leverage risk.
- Return on Equity (ROE): 14.6% - demonstrates efficient use of shareholder funds.
- Equity Ratio: ~99% - equity heavily backs assets, reflecting financial conservatism.
- Market Capitalization: ≈ ₹99,800 crores - among India's top five pharma companies by market value.
- Promoter Holding: 51.9% - stable, long-term ownership alignment.
| Metric | Value |
|---|---|
| Debt-to-Equity Ratio | 0.01 |
| Return on Equity (ROE) | 14.6% |
| Equity Ratio (Approx.) | 99% |
| Market Capitalization | ₹99,800 crores |
| Promoter Shareholding | 51.9% |
- Low total debt and near-100% equity funding reduce refinancing and interest-rate risks and provide flexibility for capex or R&D investments.
- ROE of 14.6% suggests attractive returns relative to low financial risk, implying management is generating solid profitability from equity capital.
- High promoter stake aligns strategic decisions with long-term value creation and stability.
Divi's Laboratories Limited (DIVISLAB.NS) - Liquidity and Solvency
Divi's Laboratories enters the period with a robust liquidity profile and solvency metrics that support near-term obligations while reflecting a sizable asset base. As of September 30, 2025, consolidated total assets were ₹18,151 crores, with current assets of ₹9,843 crores and non‑current assets of ₹8,308 crores. Cash on books of ₹4,205 crores gives the company high immediate liquidity, and operating cash flow coverage stands at 1.34x, indicating operating cash is 34% higher than current cash needs covered by that metric.- Cash on books: ₹4,205 crores - strong immediate liquidity buffer
- Receivables: ₹2,521 crores - manageable trade credit exposure
- Inventories: ₹3,087 crores - consistent with manufacturing and supply-chain needs
- Operating cash flow coverage ratio: 1.34 - healthy cash generation versus obligations
- Free cash flow growth: reported as 'Infinity' due to a very large year‑over‑year increase - signals volatility and the need to examine underlying causes
- Book value per share: ₹511 - reflects net asset backing per share
| Metric | Amount (₹ crores) | Notes |
|---|---|---|
| Total assets (consolidated) | 18,151 | As of Sept 30, 2025 |
| Current assets | 9,843 | Includes cash, receivables, inventories |
| Cash & cash equivalents | 4,205 | High liquidity reserve |
| Receivables | 2,521 | Trade receivables - working capital item |
| Inventories | 3,087 | Raw materials, WIP, finished goods |
| Non‑current assets | 8,308 | Property, plant, equipment, intangibles |
| Operating cash flow coverage | 1.34x | Operating cash flow / short‑term obligations proxy |
| Free cash flow growth (YoY) | Infinity | Large base effect from prior period - interpret with caution |
| Book value per share | ₹511 | Net asset value divided by outstanding shares |
Divi's Laboratories Limited (DIVISLAB.NS) - Valuation Analysis
Divi's Laboratories trades at a price-to-earnings (P/E) ratio of about 48x, signalling strong investor confidence and elevated growth expectations relative to historical averages and peers. The stock price is near ₹3,780, close to its 52-week high, reflecting sustained demand and positive market sentiment.- Market capitalization: ~₹99,800 crores - places Divi's among India's top five pharmaceutical companies by market value.
- Promoter ownership: 51.9% - indicates concentrated, stable control and alignment with long-term strategy.
- Book value per share: ₹511 - proxy for net asset value per share.
- Analyst consensus: 13 buy, 6 hold, 13 sell - mixed analyst views underscore valuation sensitivity and differing growth/profitability expectations.
- Current price context: ~₹3,780 - trading near the 52-week high, implying limited near-term downside from recent levels if momentum persists.
| Metric | Value |
|---|---|
| P/E Ratio | ~48x |
| Market Capitalization | ~₹99,800 crores |
| Promoter Holding | 51.9% |
| Share Price (approx.) | ₹3,780 |
| Book Value per Share | ₹511 |
| Analyst Recommendations | 13 Buy / 6 Hold / 13 Sell |
- Valuation premium: The ~48x P/E suggests expectations of sustained margin expansion or revenue growth; investors are pricing in a premium for quality and low-risk revenue streams.
- Risk considerations: High P/E leaves limited margin for earnings disappointment; mixed analyst ratings reflect uncertainty on near-term catalysts.
- Balance-sheet signal: Book value of ₹511 provides a tangible floor metric but is far below market price, reinforcing the growth/earnings premium component of valuation.
Divi's Laboratories Limited (DIVISLAB.NS) Risk Factors
Divi's Laboratories operates in a capital- and logistics-intensive pharmaceutical intermediates and contract manufacturing environment where margin sensitivity, supply-chain complexity and regulatory timelines create concentrated risks. Below are the principal risk vectors, quantified impacts where observable, and mitigation actions management has taken or needs to sustain.- Pricing pressure on generic APIs and intermediates: market-level pricing compression has led to gross-margin contraction in the sector; Divi's reported periods of year‑over‑year gross margin decline on certain product cohorts of 200-600 basis points when spot pricing weakened.
- Rising logistics and freight costs: during global shipping stress (notably mid‑2021 to 2023 episodes), container freight rate spikes of 30-70% (peak periods) translated into elevated COGS and working-capital needs for exporters like Divi's.
- Geopolitical disruption: Red Sea transit risks, sanctions regimes and trade-policy shifts created episodic route closures and insurance surcharges that increased landed input costs and delivery lead times.
- Supply-chain variability easing but not gone: the company has observed a gradual normalization of lead times and freight rates since late‑2023/2024, yet variability remains-company guidance suggests continued exposure to episodic spikes.
- Backward integration delays: investments in backward integration (in‑house starting-materials and captive intermediates) are intended to protect margins long term, but realized margin improvement has lagged-management commentary indicates a 6-18 month horizon before material margin benefit for many product lines.
- Peptide capacity commercialization lag: new peptide API and CDMO capacity has generated customer interest, but commercial supply requires sequential qualification steps-internal timelines and customer approvals typically span 6-24 months depending on regulatory complexity and client qualification cadence.
| Risk | Observed/Estimated Impact | Probability (near‑term) | Management Mitigation |
|---|---|---|---|
| Generic pricing pressure | Gross margin compression: ~2-6 percentage points on affected product baskets | High | Portfolio mix shift to higher-value intermediates, contract manufacturing agreements |
| Logistics & freight spikes | Freight cost increase: short-term spikes 30-70%; working capital tie‑up increased | Medium-High | Alternative routing, inventory buffering, long‑term shipping contracts |
| Geopolitical/shipping disruptions (e.g., Red Sea) | Delayed shipments, higher insurance & fuel surcharges; order postponements | Medium | Strategic route planning, contingency inventory, customer communications |
| Backward integration not fully accretive yet | Delayed margin uplift; incremental opex and capex until scale achieved | Medium | Phased ramp-up, focus on high-margin intermediates, supplier consolidation |
| Peptide capacity commercialization | Revenue recognition delayed until qualification → revenue deferral of 6-24 months | Medium | Customer trials, regulatory submissions, multi-site qualification |
- Working capital and receivables: higher logistics and longer customer qualification cycles can extend receivable days; management has historically targeted improvement in DSO but faces cyclical slowdowns during transition phases.
- Currency and input-cost exposure: raw-material import mix and INR/FX movements can amplify COGS volatility; hedging and sourcing diversification partially reduce this exposure.
- Regulatory and quality risks: new capacity-especially for peptides-requires regulatory approvals (e.g., client audits, dossier acceptance), creating timeline and revenue recognition risk.
Divi's Laboratories Limited (DIVISLAB.NS) - Growth Opportunities
Divi's Laboratories Limited is positioned for multi-year growth driven by its custom synthesis leadership, capacity expansion, nutraceutical momentum and stable promoter ownership. Key structural advantages and near-term catalysts include:
- Custom synthesis (APIs & intermediates) contributes ~40% of revenue, supplied under long-term contracts to global innovators.
- Two large USFDA‑approved manufacturing facilities located in Hyderabad and Vizag, complemented by world‑class R&D centres that support process development and customer collaboration.
- Nutraceutical division growing market share via production efficiencies and new product introductions aligned with long‑term strategies.
- Kakinada Unit‑III: partial commercial operations commenced 1 January 2025; full‑scale operations expected within ~6 months, adding meaningful upstream capacity and revenue potential.
- Stable ownership: promoters hold a 51.9% stake, supporting long‑term strategic execution.
- Strong market valuation: market capitalization ≈ ₹99,800 crores, placing Divi's among India's top five pharma firms by value.
| Metric | Value / Status |
|---|---|
| Market Capitalization | ≈ ₹99,800 crores |
| Promoter Ownership | 51.9% |
| Custom Synthesis Revenue Share | ~40% |
| USFDA‑approved Manufacturing Sites | 2 (Hyderabad, Vizag) |
| Kakinada Unit‑III Commercial Status | Partial operations from 01‑Jan‑2025; full operations expected within ~6 months |
| Nutraceuticals | Expanding market share; focus on efficiency & new SKUs |
Primary growth vectors to monitor:
- Incremental revenue and margin expansion from Kakinada Unit‑III as full operations commence.
- Deepening custom synthesis contracts with global innovators, leveraging long‑term supply agreements.
- R&D‑driven product extensions and route optimizations that lower costs and improve competitiveness.
- Scale and premiumization in nutraceuticals through new launches and production efficiencies.
Further company details and investor context: Exploring Divi's Laboratories Limited Investor Profile: Who's Buying and Why?
Divi's Laboratories Limited (DIVISLAB.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.